INS and type 2 diabetes mellitus: Our results are in line with and expand the findings of the UKPDS, in which 342 type 2 diabetes patients assigned to receive metformin showed greater reduction in macrovascular and microvascular complications, stroke, and all-cause mortality than those who received other medications (chlorpropamide, glibenclamide, or insulin) for glucose control (total n = 951) [6].